Correlation between Preoperative Ultrasonic Features of Medullary Thyroid Carcinoma and Postoperative Recurrence

Capsular Invasion ◽

Calcitonin Level ◽

Medullary Thyroid ◽

Metastatic Lymph Nodes ◽

Abstract Background: To investigate the factors that affect postoperative recurrence in medullary thyroid carcinoma (MTC) patients, including preoperative ultrasonic characteristics and other factors. Method: A retrospective analysis of seventy four MTC patients who underwent the first thyroid surgery from 2009 to 2018 and who had complete follow-up data was conducted. According to the follow-up results, these patients were divided into the recurrence group (17 cases) and non-recurrence group (57 cases). The preoperative ultrasound characteristics, preoperative and postoperative calcitonin levels, and general informations of the two groups were recorded, respectively. Univariate and multivariate analyses were performed. Results: Single factor Kaplan-Meier (K-M) analysis showed that: ① Preoperative ultrasonic characteristics including tumor size > 40.0 mm, capsular invasion, and metastatic cervical lymph nodes, as well as preoperative calcitonin level > 565.8 pg/ml, and postoperative calcitonin (within one week) level > 45.0 pg/ml were positively correlated with the risk of postoperative recurrence of MTC (P <0.05); ② There was no evidence to show that gender and age had a statistically significant effect on postoperative recurrence of MTC (P> 0.05). Multivariate Cox regression analysis showed that metastatic lymph nodes shown by ultrasound (HR=5.368, 95%CI 1.063-27.104, P=0.042) was an independent risk factor for postoperative recurrence of MTC. Conclusions: MTC patients with metastatic lymph nodes shown by ultrasound are prone to postoperative recurrence of MTC. In addition, MTC patients with a tumor > 40.0 mm, capsular invasion, preoperative calcitonin level > 565.8 pg/ml, and postoperative calcitonin level > 45.0 pg/ml are more likely to have postoperative recurrence.

Correlation between preoperative ultrasonic features of medullary thyroid carcinoma and postoperative recurrence

BMC Cancer ◽

10.1186/s12885-021-07953-y ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Qiaodan Zhu ◽

Dong Xu

Keyword(s):

Thyroid Carcinoma ◽

Lymph Nodes ◽

Capsular Invasion ◽

Calcitonin Level ◽

Medullary Thyroid ◽

Metastatic Lymph Nodes ◽

Abstract Background To investigate the factors that affect postoperative recurrence in medullary thyroid carcinoma (MTC) patients, including preoperative ultrasonic characteristics and other factors. Method A retrospective analysis of 7 MTC patients who underwent the first thyroid surgery from 2009 to 2018 and who had complete follow-up data was conducted. According to the follow-up results, these patients were divided into the recurrence group (17 cases) and non-recurrence group (57 cases). The preoperative ultrasound characteristics, preoperative and postoperative calcitonin levels, and general informations of the two groups were recorded, respectively. Univariate and multivariate analyses were performed. Results Single factor Kaplan-Meier (K-M) analysis showed that: ① Preoperative ultrasonic characteristics including tumor size > 40.0 mm, capsular invasion, and metastatic cervical lymph nodes, as well as preoperative calcitonin level > 565.8 pg/ml, and postoperative calcitonin (within one week) level > 45.0 pg/ml were positively correlated with the risk of postoperative recurrence of MTC (P < 0.05); ② There was no evidence to show that sex and age had a statistically significant effect on postoperative recurrence of MTC (P > 0.05). Multivariate Cox regression analysis showed that metastatic lymph nodes shown by ultrasound (HR = 5.368, 95%CI 1.063–27.104, P = 0.042) was an independent risk factor for postoperative recurrence of MTC. Conclusions MTC patients with metastatic lymph nodes shown by ultrasound are prone to postoperative recurrence of MTC. In addition, MTC patients with a tumor > 40.0 mm, capsular invasion, preoperative calcitonin level > 565.8 pg/ml, and postoperative calcitonin level > 45.0 pg/ml are more likely to have postoperative recurrence.

Correlation between Preoperative Ultrasonic Features of Medullary Thyroid Carcinoma and Postoperative Recurrence

10.21203/rs.3.rs-60840/v2 ◽

2020 ◽

Author(s):

Qiaodan Zhu ◽

Dong Xu

Keyword(s):

Thyroid Carcinoma ◽

Lymph Nodes ◽

Capsular Invasion ◽

Calcitonin Level ◽

Medullary Thyroid ◽

Metastatic Lymph Nodes ◽

Abstract Background: To investigate the factors that affect postoperative recurrence in medullary thyroid carcinoma (MTC) patients, including preoperative ultrasonic characteristics and other factors.Method: A retrospective analysis of 74 MTC patients who underwent first thyroid surgery from 2009 to 2018 and who had complete follow-up data was conducted. According to the follow-up results, these patients were divided into the recurrence group (17 cases) and non-recurrence group (57 cases). The preoperative ultrasound characteristics, preoperative and postoperative calcitonin level, and general information on the two groups were recorded, respectively. Univariate and multivariate analyses were performed.Results: Single factor Kaplan-Meier (KM) analysis showed that: ① Preoperative ultrasonic characteristics including tumor size > 40.0 mm, capsular invasion, and metastatic cervical lymph nodes, as well as preoperative calcitonin level > 565.8 pg/ml, and postoperative calcitonin (within one week) level > 45.0 pg/ml were positively correlated with the risk of postoperative recurrence of MTC (P <0.05); ② There was no evidence to show that gender and age had a statistically significant effect on postoperative recurrence of MTC (P> 0.05). Multivariate Cox regression analysis showed that metastatic lymph nodes shown by ultrasound (HR=5.368, 95%CI 1.063-27.104, P=0.042) were an independent risk factor for postoperative recurrence of MTC.Conclusions: MTC patients with metastatic lymph nodes as shown by ultrasound are prone to postoperative recurrence of MTC. In addition, MTC patients with a tumor > 40.0 mm, capsular invasion, preoperative calcitonin level > 565.8 pg/ml, and postoperative calcitonin level > 45.0 pg/ml are more likely to have postoperative recurrence.

Correlation Study Between Preoperative Ultrasonic Features of Medullary Thyroid Carcinoma and Postoperative Recurrence

10.21203/rs.3.rs-60840/v1 ◽

2020 ◽

Author(s):

Qiaodan Zhu ◽

Dong Xu

Keyword(s):

Lymph Node ◽

Thyroid Carcinoma ◽

Cervical Lymph Node ◽

Capsular Invasion ◽

Calcitonin Level ◽

Medullary Thyroid ◽

Abstract Background: To investigate factors that affects postoperative recurrence in medullary thyroid carcinoma (MTC) patients in terms of preoperative ultrasonic characteristics and so on. Method: A retrospective analysis of 74 MTC patients who underwent the first thyroid surgery from 2009 to 2018 at hospital and had complete follow-up information. According to the follow-up results, these patients were divided into recurrence group (17 cases) and non-recurrence group (57 cases). The preoperative ultrasound characteristics, preoperative and postoperative calcitonin level, and general information of the two groups were recorded separately. Univariate and multivariate analysis was performed. Results: Single factor KM analysis showed that: ①Preoperative ultrasonic characteristic of tumor size> 40.0 mm, capsular invasion, and abnormal cervical lymph node ,as well as preoperative calcitonin level > 565.8pg / ml, postoperative calcitonin (within one week) level > 45.0pg / ml are the factors that affect postoperative recurrence of MTC (P <0.05); ②There is no evidence shows that gender and age have statistical significance with postoperative recurrence of MTC patients (P> 0.05). Multi-factor COX regression analysis showed that abnormal cervical lymph node （HR=5.368,95%CI1.063-27.104，P=0.042）is an independent risk factor affecting postoperative recurrence of MTC patients. Conclusions: MTC patients with abnormal cervical lymph nodes prone to postoperative recurrence. In addition, MTC patients with tumor> 40.0mm, capsular invasion, preoperative calcitonin level > 565.8pg / ml, postoperative calcitonin level > 45.0pg / ml are more likely to have postoperative recurrence.

Parathyroid Glands Hyperplasias Mimicking Medullary Thyroid Carcinoma Metastatic Lymph Nodes on 18F-DOPA PET/CT

Clinical Nuclear Medicine ◽

10.1097/rlu.0000000000002633 ◽

2019 ◽

Vol 44 (8) ◽

pp. e497-e498

Author(s):

Marie Terroir ◽

Serena Grimaldi ◽

Dana Hartl ◽

Sophie Leboulleux ◽

Désirée Deandreis

Keyword(s):

Thyroid Carcinoma ◽

Lymph Nodes ◽

Parathyroid Glands ◽

Medullary Thyroid ◽

Metastatic Lymph Nodes ◽

Metastatic Lymph ◽

Pet Ct

Imaging Medullary Thyroid Carcinoma with Persistent Elevated Calcitonin Levels

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jc.2007-1211 ◽

2007 ◽

Vol 92 (11) ◽

pp. 4185-4190 ◽

Cited By ~ 176

Author(s):

Anne Laure Giraudet ◽

Daniel Vanel ◽

Sophie Leboulleux ◽

Anne Aupérin ◽

Clarisse Dromain ◽

...

Keyword(s):

Thyroid Carcinoma ◽

Bone Scintigraphy ◽

Axial Skeleton ◽

Whole Body ◽

Liver Imaging ◽

Calcitonin Level ◽

Medullary Thyroid ◽

Positron Emission ◽

Work Up

Abstract Purpose: Because calcitonin level remains elevated after initial treatment in many medullary thyroid carcinoma (MTC) patients without evidence of disease in the usual imaging work-up, there is a need to define optimal imaging procedures. Patients and Methods: Fifty-five consecutive elevated calcitonin level MTC patients were enrolled to undergo neck and abdomen ultrasonography (US); neck, chest, and abdomen spiral computed tomography (CT); liver and whole-body magnetic resonance imaging (MRI); bone scintigraphy; and 2-[fluorine-18]fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET)/CT scan (PET). Results: Fifty patients underwent neck US, CT, and PET, and neck recurrence was demonstrated in 56, 42, and 32%, respectively. Lung and mediastinum lymph node metastases in the 55 patients were demonstrated in 35 and 31% by CT and in 15 and 20% by PET. Liver imaging with MRI, CT, US, and PET in 41 patients showed liver in 49, 44, 41, and 27% patients, respectively. Bone metastases in 55 patients were demonstrated in 35% by PET, 40% by bone scintigraphy, and 40% by MRI; bone scintigraphy was complementary with MRI for axial lesions but superior for the detection of peripheral lesions. Ten patients had no imaged tumor site despite elevated calcitonin level (median 196 pg/ml; range 39–816). FDG uptake in neoplastic foci was higher in progressive patients but with a considerable overlap with stable ones. Conclusion: The most efficient imaging work-up for depicting MTC tumor sites would consist of a neck US, chest CT, liver MRI, bone scintigraphy, and axial skeleton MRI. FDG PET scan appeared to be less sensitive and of low prognostic value.

Evaluation of Ultrasonography Results in Terms of Involvement of Lymph Nodes before Thyroidectomy and Its Comparison with Pathologic Results after Thyroidectomy in Non-Medullary Thyroid Carcinoma Patients

Journal of Ardabil University of Medical Sciences ◽

10.29252/jarums.18.1.43 ◽

2018 ◽

Vol 18 (1) ◽

pp. 43-51

Author(s):

Shahriar Hashemzadeh ◽

Davood Imani ◽

Reza Javad Rashid ◽

Mohammad Kazem Tarzamani ◽

Sajjad Pourasghary ◽

...

Keyword(s):

Thyroid Carcinoma ◽

Lymph Nodes ◽

Medullary Thyroid

Management of Advanced Medullary Thyroid Carcinoma with Vandetanib: Case Series

Endocrinology and Disorders ◽

10.31579/2640-1045/065 ◽

2021 ◽

Vol 5 (1) ◽

pp. 01-07

Author(s):

Andrés Flórez R

Keyword(s):

Partial Response ◽

Adverse Events ◽

Thyroid Carcinoma ◽

Stable Disease ◽

Case Series ◽

Medullary Thyroid ◽

The Mean ◽

Grade 3

Objective: To describe the tumor response and adverse events in patients with advanced medullary thyroid carcinoma (MTC) treated with vandetanib at the National Cancer Institute in Bogotá, Colombia. Materials and Methods: Case series including five patients with advanced MTC treated with vandetanib from April 2011 to August 2018 and a minimum follow-up of 6 months. Results: 5 patients met the inclusion criteria, including 3 women. The mean age was 49 years. A total of 4 patients underwent total thyroidectomy prior to starting vandetanib. The main indication for vandetanib was progression of liver metastasis (4 patients). Regarding treatment response, 3 patients presented stable disease, 1 patient showed partial response, and 1 had disease progression. The mean treatment duration was 16.5 months. Grade 3 or 4 adverse events were observed in three patients, 1 with diarrhea, 1 with hypertension, and 1 with rash. All symptoms improved with dose reduction or temporary suspension of vandetanib. Conclusions: The management of advanced MTC with vandetanib allows for prolonged disease control (stable disease or partial response). Although adverse events are frequent, most are mild and severe cases are manageable.

Circulating Neuron-Specific Enolase in Medullary Thyroid Cancer

The International Journal of Biological Markers ◽

10.1177/172460088600100205 ◽

1986 ◽

Vol 1 (2) ◽

pp. 85-88 ◽

Cited By ~ 4

Author(s):

Furio Pacini ◽

Rossella Elisei ◽

Stefano Anelli ◽

Lucia Gasperini ◽

Ernestina Schipani ◽

...

Keyword(s):

Thyroid Carcinoma ◽

Time Course ◽

Neuron Specific Enolase ◽

High Serum ◽

Large Tumor ◽

Medullary Thyroid ◽

The Mean ◽

Metastatic Involvement

The utility of determining circulating neuron-specific enolase (NSE) in medullary thyroid carcinoma was assessed in 25 patients followed up for a mean period of 45.6 months. In 5 patients tested before any treatment serum NSE concentrations were in the normal range. After total thyroidectomy abnormally high serum NSE concentrations (more than 9.8 ng/ml) were found in 1/3 patients with normal calcitonin (CT) in remission, in 2/10 with elevated CT levels but no evidence of disease and in 9/12 with elevated CT levels and documented metastases. The mean (± SD) NSE value in this last group was 12.0 ± 12.6 ng/ml, significantly higher than in the other groups (p < 0.005). The time course of serum NSE in patients with long follow-up seems to indicate that serum NSE rises when a large tumor mass is present and usually parallels the pattern of circulating CT. Effective treatment of the metastases is usually followed by reduction of serum NSE. Thus, serum NSE can serve as an additional humoral marker for medullary thyroid carcinoma, its elevation being associated with important metastatic involvement and with a poor prognosis of the tumor.